{"product_id":"ash-2025-the-67th-annual-meeting-exposition","title":"ASH 2025: THE 67TH ANNUAL MEETING \u0026 EXPOSITION","description":"\u003cdiv class=\"prod-title\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv id=\"block-pagetitle\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"pnllearningActivityInformationClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnllearningActivityInformation_0\"\u003e\n\u003cdiv class=\"pnlLearningActivityInformationDescriptionClass\" id=\"MainContent_MainContent_ucLearningActivityCatalog_Details___learningActivityCatalog_TopAndSectionDetails_ucLearningActivityInformation_TopAndSectionDetails_rptLearningActivityInformation_pnlLearningActivityInformationDescription_0\"\u003e\n\u003cdiv class=\"product-footer\"\u003e\n\u003cdiv class=\"container\"\u003e\n\u003cdiv class=\"woocommerce-tabs wc-tabs-wrapper container tabbed-content\"\u003e\n\u003cdiv\u003e\n\u003ch3\u003eASH 2025: THE 67TH ANNUAL MEETING \u0026amp; EXPOSITION\u003c\/h3\u003e\n\u003cstrong\u003e+ Include:  videos +  pdf, size:  GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: hematologist-oncologists, pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-path-to-node=\"2\"\u003e\u003cstrong\u003eASH 2025: THE 67TH ANNUAL MEETING \u0026amp; EXPOSITION\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"3\"\u003e\u003cb\u003e“Defining the Future of Blood: Gene Therapy, Immunotherapy \u0026amp; Beyond”\u003c\/b\u003e\u003c\/h3\u003e\n\u003cbr\u003eConference Dates: December 6 – 9, 2025  Location: New Orleans, Louisiana (Ernest N. Morial Convention Center) Academic Host: American Society of Hematology (ASH)\u003cbr\u003e\u003ch2 data-path-to-node=\"6\"\u003e\n\u003cimg alt=\"ℹ️\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/2139.svg?v=1770212966\"\u003e General Information\u003c\/h2\u003e\n\u003cp data-path-to-node=\"7\"\u003eWelcome to the “Super Bowl” of Hematology. The \u003cb\u003eASH Annual Meeting\u003c\/b\u003e is the global benchmark where practice-changing data is released. If it happens in blood, it happens here.\u003c\/p\u003e\n\u003cp data-path-to-node=\"8\"\u003eThe 2025 edition in New Orleans marks a pivotal shift: we move from “experimental” gene editing to \u003cb\u003ecommercial reality\u003c\/b\u003e. This course is not just about the science; it is about the \u003cb\u003elogistics of cure\u003c\/b\u003e. From the latest CAR-T constructs for solid tumors to the real-world implementation of CRISPR for Sickle Cell Disease, this curriculum defines the standard of care for the next decade.\u003c\/p\u003e\n\u003cul data-path-to-node=\"9\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"9,0,0\"\u003e\u003cb\u003eFormat:\u003c\/b\u003e Scientific Plenary Sessions + Education Programs + Satellite Symposia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"9,2,0\"\u003e\u003cb\u003eScope:\u003c\/b\u003e Malignant Hematology (70%) \/ Non-Malignant \u0026amp; Coagulation (30%).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"11\"\u003e\n\u003cimg alt=\"👥\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f465.svg?v=1770212969\"\u003e Target Audience\u003c\/h2\u003e\n\u003cp data-path-to-node=\"12\"\u003eThis syllabus is the mandatory annual update for:\u003c\/p\u003e\n\u003col data-path-to-node=\"13\" start=\"1\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,0,0\"\u003e\u003cb\u003eHematologist-Oncologists:\u003c\/b\u003e Who need to decide between Bispecific Antibodies and CAR-T therapy for their relapsed Myeloma and Lymphoma patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,1,0\"\u003e\u003cb\u003ePathologists:\u003c\/b\u003e Integrating AI-driven diagnostics and next-gen sequencing (NGS) into daily reporting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,2,0\"\u003e\u003cb\u003eTransplant Physicians:\u003c\/b\u003e Managing the toxicities of cellular therapies (CRS\/ICANS) in an outpatient setting.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,3,0\"\u003e\u003cb\u003eGeneral Practitioners\/Hospitalists:\u003c\/b\u003e Who need to recognize the “red flags” of hematologic emergencies and manage the long-term survivors of gene therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 data-path-to-node=\"15\"\u003e\n\u003cimg alt=\"🎯\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f3af.svg?v=1770212972\"\u003e Learning Objectives\u003c\/h2\u003e\n\u003cp data-path-to-node=\"16\"\u003eBy analyzing the 2025 Late-Breaking Abstracts, participants will be able to:\u003c\/p\u003e\n\u003col data-path-to-node=\"17\" start=\"1\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,0,0\"\u003e\u003cb\u003eRevolutionize Myeloma Care:\u003c\/b\u003e Apply the 2025 algorithms for \u003cb\u003eQuadruplet Therapy\u003c\/b\u003e in newly diagnosed Multiple Myeloma and sequence BCMA-targeted agents in relapse.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,1,0\"\u003e\u003cb\u003eImplement Gene Editing:\u003c\/b\u003e Navigate the referral and management pathways for \u003cb\u003eCasgevy (Exa-cel)\u003c\/b\u003e and \u003cb\u003eLyfgenia\u003c\/b\u003e in Sickle Cell Disease and Beta-Thalassemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,2,0\"\u003e\u003cb\u003eTarget AML Precision:\u003c\/b\u003e Utilize \u003cb\u003eMenin Inhibitors\u003c\/b\u003e for KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,3,0\"\u003e\u003cb\u003eManage Hemophilia:\u003c\/b\u003e Transition patients from factor replacement to \u003cb\u003eGene Therapy\u003c\/b\u003e (Hemgenix\/Roctavian) and non-factor replacement therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 data-path-to-node=\"19\"\u003e\n\u003cimg alt=\"📚\" class=\"emoji\" draggable=\"false\" role=\"img\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/1f4da.svg?v=1770211931\"\u003e Course Topics \u0026amp; Tracks (2025 Predictions)\u003c\/h2\u003e\n\u003cp data-path-to-node=\"20\"\u003e\u003ci\u003eThe curriculum focuses on the highest-yield clinical areas.\u003c\/i\u003e\u003c\/p\u003e\n\u003ch3 data-path-to-node=\"21\"\u003e\u003cb\u003eTOPIC 1: The Myeloma \u0026amp; Lymphoma Revolution\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"22\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"22,0,0\"\u003e\u003cb\u003eBispecifics vs. CAR-T:\u003c\/b\u003e The “Great Debate.” When to use “off-the-shelf” antibodies (Teclistamab, Talquetamab) versus autologous cell therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"22,1,0\"\u003e\u003cb\u003eMCL \u0026amp; CLL:\u003c\/b\u003e Moving towards “Chemo-Free” combinations (BTK inhibitors + BCL2 inhibitors) as first-line standards.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"23\"\u003e\u003cb\u003eTOPIC 2: Leukemia \u0026amp; Myeloid Malignancies\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"24\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"24,0,0\"\u003e\u003cb\u003eAML Updates:\u003c\/b\u003e The rise of “Triplet” therapies (HMA + Venetoclax + Novel Agent) for the unfit patient.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"24,1,0\"\u003e\u003cb\u003eMDS Classification:\u003c\/b\u003e Mastering the new WHO vs. ICC classifications—it’s not just “MDS” anymore; it’s molecularly defined.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"25\"\u003e\u003cb\u003eTOPIC 3: Non-Malignant Hematology (Red Cell \u0026amp; Coag)\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"26\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"26,0,0\"\u003e\u003cb\u003eSickle Cell Cure:\u003c\/b\u003e Real-world data on the first cohort of patients treated with CRISPR gene editing—safety, off-target effects, and fertility preservation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"26,1,0\"\u003e\u003cb\u003eITP \u0026amp; TTP:\u003c\/b\u003e New agents targeting the complement system and FcRn inhibitors.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"27\"\u003e\u003cb\u003eTOPIC 4: Immuno-Oncology \u0026amp; Toxicity Management\u003c\/b\u003e\u003c\/h3\u003e\n\u003cul data-path-to-node=\"28\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"28,0,0\"\u003e\u003cb\u003eCRS \u0026amp; ICANS:\u003c\/b\u003e 2025 Protocols for managing Cytokine Release Syndrome and Neurotoxicity without admitting every patient to the ICU.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"28,1,0\"\u003e\u003cb\u003eInfection Prevention:\u003c\/b\u003e Prophylaxis strategies for the profoundly immunosuppressed patient on B-cell maturation antigen (BCMA) therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003csection class=\"related products\"\u003e\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954513907810,"sku":"MED-AMB05121","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/ASH-2025-THE-67TH-ANNUAL-MEETING-EXPOSITION.png?v=1779378686","url":"https:\/\/meducourse.com\/products\/ash-2025-the-67th-annual-meeting-exposition","provider":"Meducourse","version":"1.0","type":"link"}